Literature DB >> 22562203

MMTV-neu mice deficient in STAT1 are susceptible to develop ovarian teratomas.

Lára Hannesdóttir1, Nina Daschil, Sonja Philipp, Piotr Tymoszuk, Elisabeth Müller-Holzner, Günter Klima, Irmgard Verdorfer, Wolfgang Doppler.   

Abstract

Signal transducer and activator of transcription 1 (STAT1) serves in the protection of the organism against pathogens and other harmful insults. It is implicated in innate immune response, immunosurveillance, tumor-suppression, and the response to genotoxic as well as oxidative stress. We report here that 9 of 140 examined STAT1 deficient mouse mammary tumor virus-neu (MMTV-neu) mice developed differentiated ovarian teratomas, which histologically resemble benign dermatoid cysts. Conventional karyotyping revealed diploidy without structural rearrangements of the chromosomes. STAT1 proficient MMTV-neu mice with the same genetic background (FVB/N), and STAT1 deficient C57BL/6 mice failed to develop this type of tumor. This indicates that STAT1 deficiency promotes teratoma formation and this depends on MMTV-neu expression and/or the genetic background. Since ovarian teratomas are considered to develop as a consequence of alterations in the maturation of oocytes and follicular cells, we compared the ovaries from non-tumor bearing STAT1 deficient and proficient MMTV-neu mice. No detectable alterations in the number and proportion of the different follicular developmental stages were detected, implying the absence of non-redundant functions of STAT1 in normal folliculogenesis, as well as in follicular atresia. However, strong staining for STAT1 was detectable in granulosa and theca cells. These results point to a role for STAT1 in protecting from teratoma formation in a later step of tumorigenesis, e.g. by inducing apoptosis and eliminating premature or aberrantly formed follicles which have the potential to transform into teratomas.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22562203     DOI: 10.1387/ijdb.113397lh

Source DB:  PubMed          Journal:  Int J Dev Biol        ISSN: 0214-6282            Impact factor:   2.203


  4 in total

1.  Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy.

Authors:  Edit Porpaczy; Sabrina Tripolt; Andrea Hoelbl-Kovacic; Bettina Gisslinger; Zsuzsanna Bago-Horvath; Emilio Casanova-Hevia; Emmanuelle Clappier; Thomas Decker; Sabine Fajmann; Daniela A Fux; Georg Greiner; Sinan Gueltekin; Gerwin Heller; Harald Herkner; Gregor Hoermann; Jean-Jacques Kiladjian; Thomas Kolbe; Christoph Kornauth; Maria-Theresa Krauth; Robert Kralovics; Leonhard Muellauer; Mathias Mueller; Michaela Prchal-Murphy; Eva Maria Putz; Emmanuel Raffoux; Ana-Iris Schiefer; Klaus Schmetterer; Christine Schneckenleithner; Ingrid Simonitsch-Klupp; Cathrin Skrabs; Wolfgang R Sperr; Philipp Bernhard Staber; Birgit Strobl; Peter Valent; Ulrich Jaeger; Heinz Gisslinger; Veronika Sexl
Journal:  Blood       Date:  2018-06-14       Impact factor: 22.113

2.  Inducible, dose-adjustable and time-restricted reconstitution of STAT1 deficiency in vivo.

Authors:  Nicole R Leitner; Caroline Lassnig; Rita Rom; Susanne Heider; Zsuzsanna Bago-Horvath; Robert Eferl; Simone Müller; Thomas Kolbe; Lukas Kenner; Thomas Rülicke; Birgit Strobl; Mathias Müller
Journal:  PLoS One       Date:  2014-01-29       Impact factor: 3.240

3.  Predicting STAT1 as a prognostic marker in patients with solid cancer.

Authors:  Jinguo Zhang; Fanchen Wang; Fangran Liu; Guoxiong Xu
Journal:  Ther Adv Med Oncol       Date:  2020-05-08       Impact factor: 8.168

4.  STAT4 targets KISS1 to promote the apoptosis of ovarian granulosa cells.

Authors:  Yao Jiang; Xiaoping Xin; Xiangchun Pan; Ailing Zhang; Zhe Zhang; Jiaqi Li; Xiaolong Yuan
Journal:  J Ovarian Res       Date:  2020-11-20       Impact factor: 4.234

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.